![]() ![]() 125000003342 alkenyl group Chemical group 0.000 claims description 31.206010061218 Inflammation Diseases 0.000 claims description 33.230000004054 inflammatory process Effects 0.000 claims description 35.-1 potency Chemical class 0.000 claims description 54.125000000217 alkyl group Chemical group 0.000 claims description 57.229910052739 hydrogen Inorganic materials 0.000 claims description 468.150000003839 salts Chemical class 0.000 claims abstract description 15.239000011780 sodium chloride Substances 0.000 claims abstract description 21.102100018044 AOC3 Human genes 0.000 claims abstract description 87.150000001875 compounds Chemical class 0.000 claims abstract description 219.239000003112 inhibitor Substances 0.000 title abstract description 28.230000002401 inhibitory effect Effects 0.000 title claims abstract description 46.Publication of WO2009066152A2 publication Critical patent/WO2009066152A2/en Publication of WO2009066152A3 publication Critical patent/WO2009066152A3/en Links Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority to US98963407P priority Critical Priority to US60/989,634 priority Application filed by Pharmaxis Ltd. Priority date (The priority date is an assumption and is not a legal conclusion. ( en Inventor Ian Alexander Mcdonald Craig Ivan Turner Mandar Deodhar Jonathan Stuart Foot Original Assignee Pharmaxis Ltd. Google Patents WO2009066152A2 - Haloallylamine inhibitors of ssao/vap-1 and uses therefor WO2009066152A2 - Haloallylamine inhibitors of ssao/vap-1 and uses therefor ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |